Clozapine is the most effective
antipsychotic medication currently in use, but there has been a paucity of well-controlled research on its efficacy with people with
developmental disabilities. We present a set of guidelines to ensure proper utilization of
clozapine in individuals with
developmental disabilities, because it can offer them therapeutic advantages similar to those observed in people with
schizophrenia. We provide recommendations regarding the use of
clozapine that are based on three main sources: literature and published professional practice guidelines regarding the use of
clozapine in individuals who do not have
developmental disabilities, the limited literature on the use of
clozapine in individuals who have
developmental disabilities, and our own clinical experience. The first part of the guidelines contains an overview of necessary practical knowledge regarding side effects, dose and blood level considerations, and interactions with other medications, diet and tobacco smoking. In the second part, we offer procedures for selecting individuals for
clozapine therapy based on proper indications and
contraindications for treatment. We also include requirements regarding informed consent, dosage and special laboratory and clinical monitoring.